AT2 Stock Overview
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Atara Biotherapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.62 |
52 Week High | US$2.82 |
52 Week Low | US$0.18 |
Beta | 0.71 |
1 Month Change | -12.38% |
3 Month Change | 21.96% |
1 Year Change | -77.73% |
3 Year Change | -95.12% |
5 Year Change | -98.12% |
Change since IPO | -94.62% |
Recent News & Updates
Recent updates
Shareholder Returns
AT2 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -4.2% | -1.5% | -0.4% |
1Y | -77.7% | 28.1% | 5.0% |
Return vs Industry: AT2 underperformed the German Biotechs industry which returned 26% over the past year.
Return vs Market: AT2 underperformed the German Market which returned 6.2% over the past year.
Price Volatility
AT2 volatility | |
---|---|
AT2 Average Weekly Movement | 27.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: AT2's share price has been volatile over the past 3 months.
Volatility Over Time: AT2's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 317 | Pascal Touchon | https://www.atarabio.com |
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
Atara Biotherapeutics, Inc. Fundamentals Summary
AT2 fundamental statistics | |
---|---|
Market cap | €55.87m |
Earnings (TTM) | -€267.14m |
Revenue (TTM) | €4.18m |
15.3x
P/S Ratio-0.2x
P/E RatioIs AT2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AT2 income statement (TTM) | |
---|---|
Revenue | US$4.54m |
Cost of Revenue | US$5.73m |
Gross Profit | -US$1.18m |
Other Expenses | US$289.06m |
Earnings | -US$290.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.85 |
Gross Margin | -26.07% |
Net Profit Margin | -6,390.31% |
Debt/Equity Ratio | 0% |
How did AT2 perform over the long term?
See historical performance and comparison